<DOC>
	<DOC>NCT01167101</DOC>
	<brief_summary>Treatment strategy of post endoscopic submucosal dissection (ESD) ulcer is not yet conclusive. Rebamipide is a mucosal protective agent widely used in East Asia and has good effect on quality of ulcer healing (QOUH). The investigators will conduct this randomized controlled study to assess the effect of a combination therapy of rebamipide and proton pump inhibitor (PPI) on post ESD ulcer healing.</brief_summary>
	<brief_title>Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>patients underwent ESD for gastric adenoma or cancer subjects with previous gastric surgery subjects taking aspirin, anticoagulant, or antiplatelet agent subjects having malignancy except gastric cancer pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Rebamipide</keyword>
	<keyword>gastric ulcer</keyword>
	<keyword>healing rate</keyword>
	<keyword>iatrogenic gastric ulcer after endoscopic submucosal dissection</keyword>
</DOC>